Oxford Gene Technology sees sense 

Oxford Gene Technology (OGT), which specialises in biomarker and microarray technologies, has acquired Maidenhead-based protein array firm Sense Proteomic for an undisclosed sum.


Oxford Gene Technology (OGT), which specialises in biomarker and microarray technologies, has acquired Maidenhead-based protein array firm Sense Proteomic for an undisclosed sum.

Oxford Gene Technology (OGT), which specialises in biomarker and microarray technologies, has acquired Maidenhead-based protein array firm Sense Proteomic for an undisclosed sum.

Sense Proteomic’s technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and can also be used to monitor response to therapeutic interventions.

OGT chief executive Mike Evans commented: “This deal, combined with our recent development of an ultra-high-throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance.”

Sense Proteomic CEO Rachel Fallon said: “This transaction represents a rare
opportunity to discover important biomarkers for disease using more than one approach. The biomarkers can be detected using a simple blood test for early diagnosis and prognosis of disease. We look forward to integrating with OGT’s current capabilities and microarray expertise.”  

Nick Britton

Nick Britton

Nick was the Managing Editor for growthbusiness.co.uk when it was owned by Vitesse Media, before moving on to become Head of Investment Group and Editor at What Investment and thence to Head of Intermediary...

Related Topics